Tuesday - December 24, 2024
GSK: Blenrep Shows Significant Overall Survival Benefit, Reducing the Risk of Death by 42% in Multiple Myeloma at or After First Relapse
December 10, 2024
LONDON, England, Dec. 10 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 9, 2024:

* * *

- DREAMM-7 trial shows sustained overall survival benefit for Blenrep (belantamab mafodotin) combination versus daratumumab combination; benefit seen early and maintained through follow-up

- Data build on findings from DREAMM-7 and DREAMM-8 and support the potential for Blenrep combinations to become stan . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products